Pro Share Advisors LLC Celldex Therapeutics, Inc. Transaction History

Pro Share Advisors LLC

$42.5 Billion
Q4 2024

A detailed history of Pro Share Advisors LLC transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 18,192 shares of CLDX stock, worth $362,566. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,192

Previous 12,206 49.04%

Holding current value

$362,566

Previous $414,000 10.87%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$23.31 - $32.4 $139,533 - $193,946	5,986 Added 49.04%	18,192 $459,000
Q3 2024 Nov 13, 2024	BUY	$32.06 - $44.56 $124,456 - $172,981	3,882 Added 46.64%	12,206 $414,000
Q2 2024 Aug 13, 2024	SELL	$32.76 - $42.56 $93,103 - $120,955	-2,842 Reduced 25.45%	8,324 $308,000
Q1 2024 May 08, 2024	BUY	$35.22 - $51.88 $122,424 - $180,334	3,476 Added 45.2%	11,166 $468,000
Q4 2023 Feb 14, 2024	BUY	$22.61 - $40.65 $173,870 - $312,598	7,690 New	7,690 $304,000
Q2 2023 Aug 10, 2023	BUY	$30.29 - $38.28 $183,042 - $231,326	6,043 New	6,043 $205,000
Q4 2022 Feb 02, 2023	BUY	$27.78 - $45.38 $163,790 - $267,560	5,896 New	5,896 $262,000
Q2 2022 Aug 01, 2022	SELL	$20.5 - $37.33 $176,874 - $322,083	-8,628 Closed	0 $0
Q1 2022 May 10, 2022	SELL	$27.64 - $39.32 $39,055 - $55,559	-1,413 Reduced 14.07%	8,628 $293,000
Q4 2021 Feb 08, 2022	BUY	$35.68 - $56.27 $147,929 - $233,295	4,146 Added 70.33%	10,041 $388,000
Q3 2021 Nov 12, 2021	SELL	$28.95 - $55.99 $123,790 - $239,413	-4,276 Reduced 42.04%	5,895 $318,000
Q2 2021 Aug 13, 2021	BUY	$20.71 - $35.37 $210,641 - $359,748	10,171 New	10,171 $340,000

Others Institutions Holding CLDX

# of Institutions

197

Shares Held

60.7M

Call Options Held

960K

Put Options Held

675K

View Full List

About Celldex Therapeutics, Inc.

Ticker CLDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,772,400
Market Cap $932M
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...

More about CLDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Account

Pro Share Advisors LLC Celldex Therapeutics, Inc. Transaction History